Výsledky vyhledávání - Jeffrey A. Zonder

Upřesnit hledání
  1. 1
    Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System

    Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin... Autor Q. Ping Dou, Jeffrey A. Zonder

    Vydáno 2014
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Clinical development of novel proteasome inhibitors for cancer treatment

    Clinical development of novel proteasome inhibitors for cancer treatment Autor Huanjie Yang, Jeffrey A. Zonder, Q. Ping Dou

    Vydáno 2009
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Exportin 1 inhibition as antiviral therapy

    Exportin 1 inhibition as antiviral therapy Autor Md. Hafiz Uddin, Jeffrey A. Zonder, Asfar S. Azmi

    Vydáno 2020
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Circular RNAs in acute myeloid leukemia

    Circular RNAs in acute myeloid leukemia Autor Vijendra K. Singh, Md. Hafiz Uddin, Jeffrey A. Zonder, Asfar S. Azmi, Suresh Kumar Balasubramanian

    Vydáno 2021
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

    Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis Autor Jeffrey A. Zonder, Bart Barlogie, Brian G.M. Durie, Jason McCoy, John Crowley, Mohamad A. Hussein

    Vydáno 2006
    Získat plný text Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

    Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety Autor Ashraf Badros, Ravi Vij, Thomas C. Martin, Jeffrey A. Zonder, Lori Kunkel, Z. Wang, S. Lee, Alvin Wong, Rubén Niesvizky

    Vydáno 2013
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

    A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma Autor Jeffrey A. Zonder, Ann Mohrbacher, Seema Singhal, Frits van Rhee, William Bensinger, Han Ting Ding, John Fry, Daniel Afar, Anil Singhal

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study

    Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study Autor Suzanne Lentzsch, Galina Lagos, Raymond L. Comenzo, Jeffrey A. Zonder, Keren Osman, Samuel Pan, Divaya Bhutani, Silva Pregja, Vaishali Sanchorawala, Heather Landau

    Vydáno 2020
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

    Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232) Autor Jeffrey A. Zonder, John Crowley, Mohamad A. Hussein, Vanessa Bolejack, Dennis F. Moore, Brock Whittenberger, Muneer H. Abidi, Brian G.M. Durie, Bart Barlogie

    Vydáno 2010
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

    Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma Autor Shaji Kumar, Betsy LaPlant, Wee Joo Chng, Jeffrey A. Zonder, Natalie S. Callander, Rafaël Fonseca, Briant Fruth, Vivek Roy, Charles Erlichman, A. Keith Stewart

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

    Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase... Autor Jesús G. Berdeja, Sundar Jagannath, Jeffrey A. Zonder, Ashraf Badros, Jonathan L. Kaufman, Robert Manges, Manish Gupta, Amol Tendolkar, Mark Lynch, Eric Bleickardt, Prashni Paliwal, Ravi Vij

    Vydáno 2015
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

    The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function Autor Meletios Α. Dimopoulos, Adrián Alegre, Edward A. Stadtmauer, Hartmut Goldschmidt, Jeffrey A. Zonder, Carlos M. de Castro, Zvenyslava Masliak, Donna Reece, Marta Olesnyckyj, Zhinuan Yu, Donna M. Weber

    Vydáno 2010
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials

    Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials Autor Sikander Ailawadhi, Susanna Jacobus, Rachael Sexton, Alexander K. Stewart, Angela Dispenzieri, Mohamad A. Hussein, Jeffrey A. Zonder, John Crowley, Antje Hoering, Bart Barlogie, Robert Z. Orlowski, S. Vincent Rajkumar

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma

    A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma Autor Jatin J. Shah, Jonathan L. Kaufman, Jeffrey A. Zonder, Adam D. Cohen, William Bensinger, Brandi Hilder, Selena Rush, Duncan Walker, Brian Tunquist, Kevin Litwiler, Mieke Ptaszynski, Robert Z. Orlowski, Sagar Lonial

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Daratumumab proves safe and highly effective in <scp>AL</scp> amyloidosis

    Daratumumab proves safe and highly effective in <scp>AL</scp> amyloidosis Autor Jack Khouri, Andrew Kin, Bicky Thapa, Frederic J. Reu, Naresh Bumma, Christy Samaras, Hien Liu, Mary Ann Karam, Janice Reed, Saveta Mathur, Beth Faiman, Georgia Devries, Jeffrey A. Zonder, Jason Valent

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)

    The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus state... Autor Charalampia Kyriakou, Sean Molloy, Frank D. Vrionis, Ronald Alberico, L. Bastian, Jeffrey A. Zonder, Sergio Giralt, Noopur Raje, Robert A. Kyle, David Roodman, Meletios Α. Dimopoulos, S. Vincent Rajkumar, Brian Durie, Evangelos Terpos

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent

    Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent Autor Benjamin A. Derman, Ankit Kansagra, Jeffrey A. Zonder, Andrew Stefka, David L. Grinblatt, Larry D. Anderson, Sandeep Gurbuxani, Sunil Narula, Shayan Rayani, Ajay Major, Andrew Kin, Ken Jiang, Theodore Karrison, Jagoda Jasielec, Andrzej Jakubowiak

    Vydáno 2022
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

    First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction Autor Morie A. Gertz, Heather Landau, Raymond L. Comenzo, David C. Seldin, Brendan M. Weiss, Jeffrey A. Zonder, Giampaolo Merlini, Stefan Schönland, Jackie Walling, Gene G. Kinney, Martin Koller, Dale B. Schenk, Spencer Guthrie, Michaela Liedtke

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

    A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis Autor Vaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, Jeffrey A. Zonder, Adam D. Cohen, David C. Seldin, Angela Dispenzieri, Arnaud Jaccard, Stefan Schönland, Deborah Berg, Huyuan Yang, Neeraj Gupta, Ai-Min Hui, Raymond L. Comenzo, Giampaolo Merlini

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

    Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients Autor Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Charles Du Mond, Eftathios Kastritis, Heather Landau, Edward N. Libby, Michaela Liedtke, Giampaolo Merlini, Vaishali Sanchorawala, Stefan Schönland, Ashutosh Wechalekar, Jeffrey A. Zonder, Gene G. Kinney

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: